Clinical trials: IgAN
Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy
Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)
The objective of this study was to determine the safety and therapeutic potential of BCX9930 in participants with C3G, IgAN, or PMN.
- Conditions
- Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, Membranous Nephropathy
- Trial name
- RENEW (NCT05162066)
- Testing
- BCX9930
- Where
- 11 sites in France, Italy and 2 more
- Volunteers
- 2 people
- Sponsor
- BioCryst Pharmaceuticals
Immunoglobulin A Nephropathy
A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN
This was a 28-week, open-label, multicenter, single-group Phase 2 exploratory study to determine the safety and effect of sparsentan in participants with IgAN who are at risk of disease progression to kidney failure despite being…
- Trial name
- SPARTACUS (NCT05856760)
- Testing
- Sparsentan
- Where
- 30 sites in United States, Hong Kong
- Volunteers
- 48 people
- Sponsor
- Travere Therapeutics, Inc.
Primary IgA Nephropathy
Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy
The overall aim of the study is to evaluate the efficacy, safety, and tolerability of Nefecon 16 mg per day in the treatment of patients with primary IgAN (Immunoglobulin A nephropathy) at risk of progressing to end-stage renal…
- Trial name
- Nefigard (NCT03643965)
- Testing
- Nefecon
- Where
- 142 sites in United States, Argentina and 17 more
- Volunteers
- 365 people
- Sponsor
- Calliditas Therapeutics AB
IgA Nephropathy
Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation
Efficacy and safety of LNP023 in IgAN patients
- Trial name
- NCT03373461
- Testing
- LNP023
- Where
- 56 sites in Argentina, Australia and 23 more
- Volunteers
- 112 people
- Sponsor
- Novartis Pharmaceuticals
IgA Nephropathy
Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy
This is an open-label Phase 2a clinical study designed to evaluate the safety and efficacy of AVB-S6-500 in patients with IgA Nephropathy (IgAN). Approximately 24 patients will be enrolled.
- Trial name
- NCT04042623
- Testing
- AVB-S6-500
- Where
- 2 sites in United States, Ukraine
- Volunteers
- 1 people
- Sponsor
- Aravive, Inc.
Primary IgA Nephropathy
Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE)
This is a Phase 3b, multicenter, open-label extension (OLE) study to evaluate the efficacy and safety of Nefecon treatment in patients with IgAN who have completed the Phase 3 Study Nef-301 and continue to be treated with a…
- Trial name
- Nefigard-OLE (NCT04541043)
- Testing
- Nefecon 16mg daily
- Where
- 18 sites in United States, Argentina and 16 more
- Volunteers
- 119 people
- Sponsor
- Calliditas Therapeutics AB
Immunoglobulin A (IgA) Nephropathy
Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy
Randomized, placebo-controlled, multi-center, double-blind, proof of concept phase IIa trial and dose evaluation trial of felzartamab in IgAN
- Trial name
- IGNAZ (NCT05065970)
- Testing
- Felzartamab
- Where
- 59 sites in United States, Australia and 13 more
- Volunteers
- 54 people
- Sponsor
- HI-Bio, A Biogen Company
IgA Nephropathy, Berger Disease
Atacicept in Subjects With IgA Nephropathy
A Phase 3 Study with Atacicept in Subjects With IgA Nephropathy (ORIGIN 3)
- Trial name
- ORIGIN 3 (NCT04716231)
- Testing
- Atacicept
- Where
- United States
- Volunteers
- 428 people
- Sponsor
- Vera Therapeutics, Inc.
Lupus Nephritis, Immunoglobulin A Nephropathy
Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study of ALXN2050 (120 and 180 milligrams [mg]) in addition to background therapy consistent with the standard of care in adult participants (≥ 18 to ≤…
- Conditions
- Lupus Nephritis, Immunoglobulin A Nephropathy, IgAN, LN
- Trial name
- NCT05097989
- Testing
- ALXN2050
- Where
- 71 sites in United States, Argentina and 14 more
- Volunteers
- 100 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
IgA Nephropathy
Efficacy and Safety of Atacicept in IgA Nephropathy
This main purpose of this study was to evaluate the safety, tolerability, dose response and efficacy of Atacicept in participants with IgA nephropathy and persistent proteinuria.
- Trial name
- NCT02808429
- Testing
- Atacicept 25 mg, Atacicept 75 mg
- Where
- 18 sites in United States, Japan and 1 more
- Volunteers
- 16 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
IgA Nephropathy, Immunoglobulin A Nephropathy
Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy
The ASSIST study was a phase 2, double-blind, placebo-controlled crossover study to evaluate the safety and efficacy of atrasentan vs.
- Trial name
- ASSIST (NCT05834738)
- Testing
- Atrasentan
- Where
- 30 sites in United States, Australia and 4 more
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
Immunoglobulin A Nephropathy, IgAN - IgA Nephropathy
First in Human Study to Assess Safety of VIS649 in Healthy Subjects
This is a phase 1, randomized, placebo-controlled, double-blind, single ascending dose study of IV VIS649 in healthy subjects. VIS649 is a monoclonal immunoglobulin G2 (IgG2) antibody targeting the B-cell growth factor APRILL.
- Conditions
- Immunoglobulin A Nephropathy, IgAN - IgA Nephropathy, IgA Nephropathy
- Trial name
- NCT03719443
- Testing
- VIS649
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
IgA Nephropathy, Lupus Nephritis
Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
This is a Phase II trial assessing the safety and preliminary efficacy of daily APL-2 subcutaneous infusion administered for 16 weeks with a 6 month safety follow up, in patients with glomerulopathies
- Conditions
- IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, C3 Glomerulonephritis
- Trial name
- NCT03453619
- Testing
- APL-2
- Where
- 17 sites in United States
- Volunteers
- 21 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Lupus Nephritis, Immunoglobulin A Nephropathy
Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
The objectives of this study are to evaluate the safety and efficacy of ravulizumab administered by intravenous (IV) infusion compared to placebo and demonstrate proof-of-concept of the efficacy of terminal complement inhibition…
- Trial name
- SANCTUARY (NCT04564339)
- Testing
- Ravulizumab, Background Therapy
- Where
- 64 sites in United States, Australia and 10 more
- Volunteers
- 123 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Immunoglobulin A Nephropathy, Glomerular Disease
Safety and Efficacy Study of VIS649 for IgA Nephropathy
The purpose of this study is to evaluate the efficacy and safety of VIS649 in participants with immunoglobulin A (IgA) Nephropathy (IgAN)
- Conditions
- Immunoglobulin A Nephropathy, Glomerular Disease, IgAN
- Trial name
- NCT04287985
- Testing
- Low Dose-VIS649, Medium Dose-VIS649, High Dose-VIS649
- Where
- 93 sites in United States, Australia and 13 more
- Volunteers
- 155 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Immunoglobulin A Nephropathy
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
To determine the long-term (approximately 2 years) nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with immunoglobulin A nephropathy (IgAN).
- Trial name
- PROTECT (NCT03762850)
- Testing
- sparsentan, irbesartan, Dapagliflozin
- Where
- 162 sites in United States, Australia and 16 more
- Volunteers
- 406 people
- Sponsor
- Travere Therapeutics, Inc.
Immunoglobulin A Nephropathy
Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade
The primary safety objective of this study is to evaluate the safety and tolerability of CCX168 in subjects with IgAN on background supportive therapy with a maximally tolerated dose of RAAS blockade.
- Trial name
- NCT02384317
- Testing
- CCX168
- Where
- 6 sites in United States, Sweden
- Volunteers
- 7 people
- Sponsor
- Amgen
IgA Nephropathy (IgAN), Berger Disease
A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)
The purpose of this study is to evaluate the effect of cemdisiran on proteinuria in adults with immunoglobulin A nephropathy (IgAN), who excrete >1 gram (gm) of protein per day despite standard of care, which includes treatment…
- Conditions
- IgA Nephropathy (IgAN), Berger Disease, Glomerulonephritis, IgA
- Trial name
- NCT03841448
- Testing
- Cemdisiran
- Where
- 17 sites in Canada, France and 7 more
- Volunteers
- 31 people
- Sponsor
- Alnylam Pharmaceuticals
IgA Nephropathy
Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
The primary objective of this study is to evaluate the effect of OMS721 on 24-hour urine protein excretion (UPE) in IgA nephropathy (IgAN) patients with high baseline proteinuria (high-risk proteinuria group; 24-hour UPE ≥ 2…
- Trial name
- NCT03608033
- Testing
- OMS721, Vehicle (D5W or saline)
- Where
- 139 sites in United States, Argentina and 21 more
- Volunteers
- 360 people
- Sponsor
- Omeros Corporation
IgA Nephropathy, CKD Associated With Type 1 Diabetes
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
This multi-center, open-label Phase 2 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with the following rare chronic kidney diseases (CKD): CKD associated with type 1 diabetes…
- Conditions
- IgA Nephropathy, CKD Associated With Type 1 Diabetes, Focal Segmental Glomerulosclerosis, Autosomal Dominant Polycystic Kidney
- Trial name
- PHOENIX (NCT03366337)
- Testing
- Bardoxolone methyl capsules
- Where
- 30 sites in United States
- Volunteers
- 103 people
- Sponsor
- Biogen